Middle East & Africa Gastrointestinal Drugs Market Growth and Recent Trends by 2027
Historic Data: 2017-2018 | Base Year: 2019 | Forecast Period: 2020-2027Middle East & Africa Gastrointestinal Drugs Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Drug Class (Acid Neutralizers, Antidiarrheal and Laxatives, Anti-Inflammatory Drugs, Antiemetic and Antinauseants, Biologics, and Others); Route of Administration (Oral, and Parenteral); Application (Inflammatory Ulcerative Colitis, Crohn's Disease, Irritable Bowel Syndrome, Gastroenteritis, Celiac Disease, and Others); and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Country
- Report Date : Nov 2020
- Report Code : TIPRE00016306
- Category : Life Sciences
- Status : Published
- Available Report Formats :
- No. of Pages : 140
The Middle East & Africa gastrointestinal drugs market is expected to reach US$ 2,573.94 million by 2027 from US$ 2,000.27 million in 2019; it is estimated to grow at a CAGR of 3.3 % from 2020 to 2027.
Rising prevalence of gastrointestinal (GI) diseases, and increase in development of biologics are the key factors driving the growth of gastrointestinal drugs. However, side effects associated with the drugs is the major factor hindering the market growth in Asia Pacific.
Gastrointestinal (GI) disorders are the medical conditions related to the digestive system that affect the colon, small and large intestine, and rectum. The disorders include constipation, irritable bowel, ulcerative colitis, and peptic ulcer diseases. These disorders are characterized by various symptoms such as pain, bloating, diarrhoea, nausea, and vomiting. These disorders constitute a large proportion of outpatients and frequent hospital visits. A wide range of GI drugs is commercially available in the market for the treatment of various conditions. Additionally, rising investments in the development of biologics and the emergence of a biosimilar are expected to drive the growth of the Middle East & Africa Gastrointestinal Drugs market in the forecast period.
Gastrointestinal diseases are becoming prevalent. Rapidly progressing research activities in drug development of novel therapeutics are driving the growth of the market. Many research institutes are offering funding to accelerate the discovery of novel methods for the treatment of GI disorders, which is offering lucrative opportunities for the discovery of new therapies. The major research areas are understanding mechanisms responsible for pancreatic inflammation and pancreatitis genetics and immunobiology of inflammatory bowel disease.
Moreover, the pharmaceutical industry is continually evolving. There is always a need for new, innovative therapeutic approaches in the treatment of various GI indications. The GI candidates-based pipeline is growing for a wide range of therapeutic applications, including Crohn's disease, Ulcerative colitis, inflammatory bowel disease, and others. Many big and small pharmaceutical companies are engaged in the development of several GI biologics drugs. Thus, the growing innovative pipeline of GI drugs is, in turn, boosting the drug discovery activities across the industry.
Middle East countries have registered a growth in the number of COVID cases in the last few days, with the UAE registering 85,595 cases, Saudi Arabia reporting 336,766, and South Africa indicating 682,215 confirmed cases. However, gastrointestinal drug market in this pandemic is on rising, due to the increasing awareness about treatments of gastrointestinal disorders in the region.
Rest of Middle East & Africa Gastrointestinal drugs Market, Revenue and Forecast to 2027 (US$ Mn)
- This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SEGMENTATION
By Drug Class
- Acid Neutralizers
- Antidiarrheal and Laxatives
- Anti-Inflammatory Drugs
- Antiemetic and Antinauseants
- Biologics
- Others
By Route of Administration
- Oral
- Parenteral
By Application
- Inflammatory Ulcerative Colitis
- Crohn's Disease
- Irritable Bowel Syndrome
- Gastroenteritis
- Celiac Disease
- Others
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Country
- Saudi Arabia
- UAE
- South Africa
- Rest of Middle East and Africa
Company Profiles
- Johnson and Johnson Services, Inc.
- GlaxoSmithKline plc
- Celltrion Healthcare Co.,Ltd.
- AstraZeneca
- Takeda Pharmaceutical Company Limited
Middle East & Africa Gastrointestinal Drugs Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2019 | US$ 2,000.27 Million |
| Market Size by 2027 | US$ 2,573.94 Million |
| Global CAGR (2020 - 2027) | 3.3 % |
| Historical Data | 2017-2018 |
| Forecast period | 2020-2027 |
| Segments Covered |
By Drug Class
|
| Regions and Countries Covered | Middle East and Africa
|
| Market leaders and key company profiles |
Market Research & Consulting
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Testimonials
I wish to appreciate your support and the professionalism you displayed in the course of attending to my request for information regarding to infectious disease IVD market in Nigeria. I appreciate your patience, your guidance, and the fact that you were willing to offer a discount, which eventually made it possible for us to close a deal. I look forward to engaging The Insight Partners in the future, all thanks to the impression you have created in me as a result of this first encounter.
DR CHIJIOKE ONYIA, MANAGING DIRECTOR, PineCrest Healthcare Ltd.
The Insight Partners delivered insightful, well-structured market research with strong domain expertise. Their team was professional and responsive throughout. The user-friendly website made accessing industry reports seamless. We highly recommend them for reliable, high-quality research services
Yukihiko Adachi CEO, Deep Blue, LLC.Reason to Buy
- Informed Decision-Making
- Understanding Market Dynamics
- Competitive Analysis
- Customer Insights
- Market Forecasts
- Risk Mitigation
- Strategic Planning
- Investment Justification
- Identifying Emerging Markets
- Enhancing Marketing Strategies
- Boosting Operational Efficiency
- Tracking Industry Innovations
- Aligning with Regulatory Trends
Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.
Absolutely — analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.
Once your order is successfully placed, you will receive a confirmation email along with your invoice.
• For published reports: You’ll receive access to the report within 4–6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.
We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we’ll be happy to provide a customized proposal or scope.
The report is available in either PDF format or as an Excel dataset, depending on the license you choose.
The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.
Our payment process is fully secure and PCI-DSS compliant.
We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.
Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we’re happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you’re considering, and we’ll share a personalized quote.
Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report’s scope, methodology, customization options, or which license suits you best, we’re here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.
Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we’ll be happy to assist.
Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we’ll ensure the issue is resolved quickly so you can access your report without interruption.
- Johnson and Johnson Services, Inc.
- GlaxoSmithKline plc
- Celltrion Healthcare Co.,Ltd.
- AstraZeneca
- Takeda Pharmaceutical Company Limited
Get Free Sample For